Potential emerging therapeutic strategies to prevent restenosis in the peripheral vasculature

Catheterization and Cardiovascular Interventions

Volumn 56, Issue 3, 2002, Pages 421-431

  Schainfeld, Robert M ^a  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

Aortoiliac disease; Arterial restenosis; Femoropopliteal disease; Intermittent claudication; Percutaneous and surgical revascularization; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOPEPTIN; ANTITHROMBOCYTIC AGENT; BERAPROST; CILOSTAZOL; CLOPIDOGREL; CYCLOSPORIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ELASTASE; KETANSERIN; LAZAROID; LINSIDOMINE; LOW MOLECULAR WEIGHT HEPARIN; NAROPARCIL; NITRIC OXIDE DONOR; PROBUCOL; SAPORIN; TICLOPIDINE; TRANILAST; TRAPIDIL;

ANGIOPLASTY; ARTICLE; BRACHYTHERAPY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG ACTIVITY; ENDOVASCULAR SURGERY; GENE THERAPY; HUMAN; META ANALYSIS; PATHOPHYSIOLOGY; PERIPHERAL CIRCULATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROBLEM SOLVING; RESTENOSIS; REVASCULARIZATION; SKILL; TECHNOLOGY; THROMBOSIS PREVENTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANIMALS; BLOOD VESSELS; BRACHYTHERAPY; CONSTRICTION, PATHOLOGIC; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; GENETIC THERAPY; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PLATELET AGGREGATION INHIBITORS; PROBUCOL; RECONSTRUCTIVE SURGICAL PROCEDURES; STENTS; TETRAZOLES; TICLOPIDINE; VASODILATION; VASODILATOR AGENTS;

EID: 0036296886     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10211     Document Type: Article

References (68)

1. Redefining the treatment of peripheral artery disease
2. Management of peripheral arterial disease (PAD)
3. Restenosis of endovascular stents from stent compression
4. The three processes leading to post PTCA restenosis: Dependence on the lesion substrate
5. Prevention of restenosis after percutaneous coronary interventions: The medical approach
6. Myointimal hyperplasia: Basic science and clinical considerations
7. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty
8. Effects of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture
9. The potential of cilostazol in interventional cardiology
10. Impact of cilostazol on neointimal proliferation following Palmaz-Schatz stent implantation: A prospective randomized trial
11. Impact of cilostazol on intimal proliferation after directional coronary atherectomy
12. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty
13. Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation
14. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation
15. Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction
16. A randomized comparison of cilostazol vs. ticlopidine after coronary stent implantation
17. Comparison of cilostazol with ticlopidine after Palmaz-Schatz stent implantation: A prospective randomized trial
18. Usefulness of cilostazol versus ticlopidine in coronary artery stenting
19. Comparison of cilostazol versus ticlopidine therapy after stent implantation
20. Prevention of coronary restenosis
21. Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty
22. Preventive effects of trapidil (PDGF antagonist) on restenosis after PTCA
23. Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty
24. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty
25. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: The probucol angioplasty restenosis trial
26. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis
27. Efficacy of tranilast on restenosis after coronary angioplasty: Is there any rebound phenomenon after ceasing tranilast at 3 months?
28. Effectiveness of tranilast on restenosis after directional coronary atherectomy
29. Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty
30. Long-term effects of angiopeptin treatment in coronary angioplasty
31. Double blind, controlled trial of the effect of angiopeptin on coronary restenosis following balloon angioplasty
32. Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty
33. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
34. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting
35. Antithrombotic therapy in peripheral arterial occlusive disease
36. Endovascular stems and stent-grafts: Is heparin coating desirable?
37. Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery
38. Adjuvant medical therapy in peripheral bypass surgery
39. Antiplatelet therapy and other interventions after revascularisation procedures in patients with peripheral arterial disease: A meta-analysis
40. Antithrombotic agents after peripheral transluminal angioplasty: A review of the studies, methods and evidence for their use
41. Cilostazol: Treatment of intermittent claudication
42. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries
43. Comparison of cilostazol with warfarin as antithrombotic therapy after femoro-popliteal bypass surgery using an ePTFE graft
44. Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting
45. Low-molecular-weight heparin (reviparin) reduces the incidence of femoropopliteal in-stent stenosis: Preliminary results of an ongoing study
46. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: Results of a randomized double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial)
47. Effect of elastase on primary graft patency after femoralpopliteal arterial bypass for arteriosclerosis obliterans: A randomized, controlled study
48. Effect of pancreatopeptidase E (Elastase) on the suppression of intimal fibrous proliferation after arterial reconstruction in high cholesterol-fed rabbits
49. Iloprost reduces peripheral resistance during femoro-distal reconstruction
50. Effects of perioperative iloprost on patency of femorodistal bypass grafts
51. Endovascular brachytherapy for peripheral vascular disease
52. Vascular brachytherapy: Update on clinical trials
53. Prophylactic endovascular radiotherapy to prevent intimal hyperplasia after stent implantation in femoropopliteal arteries
54. 192IR endovascular brachytherapy for avoidance of intimal hyperplasia after percutaneous transluminal angioplasty and stent implantation in peripheral vessels: 6 Years of experience
55. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty
56. Intravascular radiation for prevention of restenosis after angioplasty of narrowed femoral-popliteal arteries: Preliminary six month results of a feasibility study
57. Clinical protocol: Arterial gene therapy for restenosis
58. Arterial gene therapy for inhibiting restenosis in patients with claudication undergoing superficial femoral artery angioplasty
59. Induction of p-53 mediated apoptosis and local hepatocyte growth factor (HGF) by cyclic AMP accumulation in human aortic VSMC
60. Hepatocyte growth factor is a novel member of endothelium-specific growth factors: Additive stimulatory effect of hepatocyte growth factor with fibroblast growth factor but not with vascular endothelial growth factor
61. Photoangioplasty: An emerging clinical cardiovascular role for photodynamic therapy
62. Use of locally delivered conventional drug therapies
63. Local heparin delivery following balloon angloplasty to prevent restenosis: Preliminary results of an open multicenter registry
64. Local delivery of enoxaparin to decrease restenosis after stenting: Results of initial multicenter trial - Polish-American Local Lovenox NIR Assessment study (The POLONIA study)
65. Heparin-coated Palmaz-Schatz stents in human coronary arteries
66. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study
67. Effect on intimal hyperplasia of dexamethasone released from coated metal stents compared with non-coated stents in canine femoral arteries
68. Electro-encapsulating drugs within blood platelets: Local delivery to injured arteries during angioplasty